MedTrace Logo

U-500R Insulin In Type 2 Diabetes With Severe Insulin Resistance Via Omnipod

NCT00606034 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2014-02-06

Study results available
· View outcomes & findings →

Summary

Patients with Type 2 diabetes and severe insulin resistance with very large insulin requirements who have failed all previous insulin regimens using non-concentrated forms of insulin (U100 insulin formulations) will receive 5X concentrated insulin (U500 regular insulin)infused via insulin pump.

Conditions

Interventions

DRUG

U-500 Insulin delivered by Omnipod (disposable insulin pump)

U-500 insulin (concentrated insulin) will be infused continuously subcutaneously using a disposable insulin pump called an Omnipod; the insulin infusion dosage will be individualized to each subject's needs

Sponsors & Collaborators

  • Mountain Diabetes and Endocrine Center

    lead OTHER

Principal Investigators

  • Wendy S Lane, MD · Mountain Diabetes and Endocrine Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00606034 on ClinicalTrials.gov